Merck (MSD) has signed a definitive agreement to acquire all outstanding shares of Pappas Capital’s portfolio company VelosBio through a subsidiary for $2.75bn in cash, subject to certain customary adjustments.
Pioneer in cancer therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1), VelosBio is developing VLS-101, an investigational ADC comprising a monoclonal antibody.
Go deeper with GlobalData
The acquisition will strengthen Merck’s oncology pipeline with the addition of VelosBio’s lead investigational candidate VLS-101.
The antibody-drug conjugate that targets ROR1 is currently being evaluated in Phase I and Phase II clinical trials to treat patients with hematologic malignancies and solid tumours, respectively.
In the preclinical mouse models of human hematologic malignancies and solid tumours, VLS-101 demonstrated robust antitumour activity.
Furthermore, the US Food and Drug Administration (FDA) granted orphan drug and fast track designations to VLS-101 for the treatment of mantle cell lymphoma (MCL).
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataMerck Research Laboratories president Dr Roger Perlmutter said: “At Merck, we continue to bolster our growing oncology pipeline with strategic acquisitions that both complement our current portfolio and strengthen our long-term growth potential.
“Pioneering work by VelosBio scientists has yielded VLS-101, which in early studies has provided notable evidence of activity in heavily pretreated patients with refractory haematological malignancies, including mantel cell lymphoma and diffuse large B-cell lymphoma.”
Subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions, the closing of the deal should take place by the end of the year.
Last month, VelosBio began a Phase II trial to analyse VLS-101 for treating patients with solid tumours, including those with triple-negative breast cancer (TNBC), hormone receptor-positive and/or HER2-positive breast cancer and non-squamous non-small-cell lung cancer (NSCLC).
